

Company name-----ProPhet----- * Website-----www.pro-phet.com----- *

Select a CATEGORY: Biotech/Pharma

(Delete categories you are not selecting)

Select one SESSION per abstract from the list below *

(Delete sessions you are not selecting)

How AI Is Rewiring Pharma R&D: From Molecules to Models to Quantum Technology

- **Executive Summary / Investment Rational:**
ProPhet is an AI-driven platform that explores billions of molecules from sequence alone, enabling large-scale discovery of novel chemotypes and access to hard-to-drug targets. By combining broad screening with focused prioritization, it increases the likelihood of identifying true binders. The company is collaborating with pharma partners including Merck and AstraZeneca and has demonstrated experimental validation results supporting its predictions.
- **Core Technology:**
ProPhet's platform uses sequence-based models to infer protein–ligand interaction landscapes, enabling direct prediction of binding without structural data. This approach supports rapid, large-scale screening and effective prioritization across targets, including those lacking high-quality structural information.
- **Product Profile/Pipeline:**
ProPhet's product is a multi-stage AI platform that narrows vast chemical space into a small set of high-probability hits, combining automated screening with researcher-guided refinement to enable broader, diverse chemical exploration. The platform demonstrates millisecond-scale search and has shown experimentally validated hit identification, with strong market potential in accelerating discovery for complex or data-poor targets.
- **Business Strategy:**
ProPhet follows a staged model: initial discovery collaborations generate validation and revenue, followed by deployment of embedded platform solutions within pharma workflows, and long-term strategic partnerships with shared downstream economics.
- **What's Next?**
Key next steps include completing ongoing pharma collaborations, expanding experimental validation, and scaling partnerships. The company plans to grow its R&D team and convert pilot projects into paid platform deployments and long-term agreements.